1h Free Analyst Time
The clostridium diagnostics market is forecasted to grow by USD 3.16 billion during 2023-2028, accelerating at a CAGR of 16.83% during the forecast period. The report on the clostridium diagnostics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing prevalence of CDI, rise in aging population, and development of novel therapies.
The clostridium diagnostics market is segmented as below:
By Technology
- Immunoassays
- Molecular diagnostics
By Product
- Clostridium difficile
- Clostridium perfringens
- Clostridium botulinum
- Clostridium tetani
- Clostridium sordellii
By End-user
- Hospitals
- Independent laboratories
- Physicians clinics
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the clostridium diagnostics market covers the following areas:
- Clostridium diagnostics market sizing
- Clostridium diagnostics market forecast
- Clostridium diagnostics market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. IT presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Technology
7 Market Segmentation by Product
8 Market Segmentation by End-user
9 Customer Landscape
10 Geographic Landscape
11 Drivers, Challenges, and Opportunity/Restraints
12 Competitive Landscape
13 Competitive Analysis
14 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global clostridium diagnostics market: AstraZeneca PLC, Beckman Coulter Inc., Becton Dickinson and Co., bioMerieux SA, DiaSorin SpA, F. Hoffmann La Roche Ltd., Ferring BV, Fujirebio Holdings Inc., Hologic Inc., Huvepharma EOOD, Meridian Bioscience Inc., Novartis AG, Olympus Corp., Pfizer Inc., QIAGEN NV, Siemens AG, Summit Therapeutics Inc., TECHLAB Inc., Thermo Fisher Scientific Inc., and Trinity Biotech PLC.Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is development of new vaccines."
According to the report, one of the major drivers for this market is the growing prevalence of CDI.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AstraZeneca Plc
- Beckman Coulter Inc.
- Becton Dickinson and Co.
- bioMerieux SA
- DiaSorin SpA
- F. Hoffmann La Roche Ltd.
- Ferring BV
- Fujirebio Holdings Inc.
- Hologic Inc.
- Huvepharma EOOD
- Meridian Bioscience Inc.
- Novartis AG
- Olympus Corp.
- Pfizer Inc.
- QIAGEN NV
- Siemens AG
- Summit Therapeutics Inc.
- TECHLAB Inc.
- Thermo Fisher Scientific Inc.
- Trinity Biotech Plc
